Tuesday, 10 Jun 2025
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA
logo logo
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
  • 🔥
  • Trump
  • House
  • White
  • VIDEO
  • ScienceAlert
  • Trumps
  • Watch
  • man
  • Health
  • Colossal
Font ResizerAa
American FocusAmerican Focus
Search
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
Follow US
© 2024 americanfocus.online – All Rights Reserved.
American Focus > Blog > Health and Wellness > Woman Dies After Using Weight-Loss Drug In U.K.’s First Case
Health and Wellness

Woman Dies After Using Weight-Loss Drug In U.K.’s First Case

Last updated: November 9, 2024 9:12 pm
Share
Woman Dies After Using Weight-Loss Drug In U.K.’s First Case
SHARE

A tragic incident has occurred in the U.K. involving a 58-year-old nurse named Susan McGowan who passed away after taking two doses of the weight-loss medication tirzepatide, also known as Mounjaro or Zepbound. According to reports, McGowan’s death was attributed to multiple organ failure, septic shock, and pancreatitis, with the Eli Lilly drug listed as a contributing factor on her death certificate.

McGowan had purchased the prescription for tirzepatide online and had taken two low doses of the drug over a period of two weeks. Shortly after her second dose, she began experiencing severe stomach pain and sickness, prompting her to seek treatment at University Hospital Monklands where she had worked for three decades. Unfortunately, her condition worsened, leading to kidney issues, coma, and eventually organ failure.

Tirzepatide is categorized as a GLP-1 receptor agonist, a class of weight-loss drugs that help reduce appetite by inducing a feeling of fullness. Similar to Novo Nordisk’s Ozempic, tirzepatide is known for its effectiveness in weight loss and managing type two diabetes. However, it is also associated with side effects such as vomiting, diarrhea, and nausea, and in rare cases, severe allergic reactions, kidney problems, stomach issues, and thyroid tumors.

Despite these risks, regulatory authorities maintain that the benefits of tirzepatide outweigh the potential drawbacks. The U.K.’s Medicines and Healthcare products Regulatory Authority approved the drug as a weight loss aid in 2023, closely monitoring adverse events through the Yellow Card reporting scheme. While a second death is under investigation for possible links to tirzepatide, no conclusive evidence has been established.

In response to the incident, Dr. Alison Cave, Chief Safety Officer at MHRA, emphasized the organization’s commitment to patient safety and the rigorous assessment of medicines before approval. Eli Lilly, the manufacturer of tirzepatide, also reiterated its dedication to monitoring and reporting safety information for all its products.

See also  Red and processed meat consumption associated with higher type 2 diabetes risk, study of 2 million people finds

As investigations continue into the circumstances surrounding Susan McGowan’s tragic death, it serves as a poignant reminder of the importance of patient safety and thorough evaluation of medication risks and benefits. Our thoughts are with McGowan’s family during this difficult time, and we hope that lessons learned from this incident will contribute to enhanced safety measures in the healthcare industry.

TAGGED:caseDiesDrugU.K.sWeightLossWoman
Share This Article
Twitter Email Copy Link Print
Previous Article Emilia Wickstead Resort 2025 Collection Emilia Wickstead Resort 2025 Collection
Next Article Days Before The Election Trump Melts Down Because He Isn’t Running Against Biden Days Before The Election Trump Melts Down Because He Isn’t Running Against Biden
Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Popular Posts

Ten Years of the Loewe Puzzle Bag: A Cubist Classic Celebrates a Decade

After a decade of captivating the fashion world with its innovative design and impeccable craftsmanship,…

May 29, 2025

Migrant, 2 teens charged with robbing boys in Hyde Park

An 18-year-old Venezuelan migrant and two juveniles are facing charges in connection with a robbery…

May 26, 2025

Prevalence of firearms in US drives public health crisis of gun deaths, study finds

The prevalence of firearms in the United States has become a significant public health crisis,…

September 9, 2024

8 Art Books to Read This Pride Month

In a recent interview, writer James Baldwin reflected on his mentor Beauford Delaney, a queer…

June 1, 2025

‘Caught in the Lie’ Docuseries Trailer

Sherri Papini, who made headlines in 2016 after her alleged abduction and subsequent disappearance, is…

May 1, 2025

You Might Also Like

The Real Medicaid Crisis Isn’t Cuts—It’s The Model Itself
Health and Wellness

The Real Medicaid Crisis Isn’t Cuts—It’s The Model Itself

June 10, 2025
Organ transplant groups use loophole to boost ratings
Health and Wellness

Organ transplant groups use loophole to boost ratings

June 10, 2025
Orgasms aren’t the sole key to women’s sexual satisfaction, study finds
Health and Wellness

Orgasms aren’t the sole key to women’s sexual satisfaction, study finds

June 10, 2025
Frank Sinatra’s Mob Ties Exposed In 2,400 Pages of FBI Case Notes
Celebrities

Frank Sinatra’s Mob Ties Exposed In 2,400 Pages of FBI Case Notes

June 10, 2025
logo logo
Facebook Twitter Youtube

About US


Explore global affairs, political insights, and linguistic origins. Stay informed with our comprehensive coverage of world news, politics, and Lifestyle.

Top Categories
  • Crime
  • Environment
  • Sports
  • Tech and Science
Usefull Links
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA

© 2024 americanfocus.online –  All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?